The Alkaloid #20: The Oldest Trip

The Dose

Every psychedelic has an origin story, and most of them are recent. LSD was born in a Swiss lab in 1938. Psilocybin got its name in 1958. Mescaline is the outlier. People in what is now northern Mexico and south Texas were eating peyote roughly 5,700 years ago, which makes it the oldest psychedelic anyone can put a date on. Archaeologists have the dried, radiocarbon-dated buttons to prove it.

Here is the odd part. The molecule humanity has used the longest is the one neuroscience knows the least about. LSD and psilocybin have been scanned, mapped, and modeled for twenty years. Mescaline sat most of that out. Peyote grows slowly and is legally and culturally protected, tangled up with the Native American Church and a genuine conservation problem, and researchers chasing pharmaceutical money tended to go where the patents were. The grandfather of the field quietly became its blind spot.

This summer a team at Northeastern finally put it under a scanner. The oldest trip, it turns out, has a signature all its own — and it is not the one LSD and psilocybin leave behind.

Quick Hits

Terpenes are doing more than smelling nice. A new Israeli study reported that several cannabis terpenes activate the CB1 and CB2 receptors directly, not just alongside THC. That gives the long-argued "entourage effect" some real molecular footing instead of marketing copy.

Pain relief without the head change. Researchers described a cannabis-derived compound that eased pain in animal models without producing intoxication, the kind of separation that has quietly become one of the field's most valuable goals.

One fingerprint, five doors. The largest psychedelic brain-imaging study yet — 267 people, five different drugs, mescaline among them — found a single shared signature underneath the chemistry. We take that one apart in Thursday's Field Note.

That's the news. The analysis is below — Science Desk, Market Watch, and a closing thought.

Science Desk

The study came out of Northeastern's Center for Translational Neuroimaging, from doctoral researcher Noah Cavallaro and professor Craig Ferris, and was published in Neuroscience Bulletin on May 21. The method is the interesting bit: awake-animal fMRI. Twenty-four rats, given mescaline, scanned while conscious rather than anesthetized, then run through sensory tests using sound and smell.

The headline finding lands on a part of the brain most people never think about. The cerebellum is usually filed under motor control, the body's autopilot. Under mescaline it did something contradictory. Internally it went quiet — the team describes "cerebellar-selective BOLD suppression" — while at the same time it wired up louder to the rest of the brain, showing what they call global hyperconnectivity with the hippocampus, thalamus, sensory cortex, and midbrain. Picture a filter that turns down its own volume while shouting at everyone downstream.

The acoustic test made that concrete. They measured prepulse inhibition, which is the brain's knack for softening a startle when a faint warning comes first. Under mescaline the rats filtered some frequencies better than usual (a 27.6% gain at 4 kHz, 27.3% at 20 kHz) and one frequency noticeably worse (a 16.4% drop at 12 kHz). The gate wasn't broken. It was re-tuned, letting some of the world through unedited while clamping down on the rest.

Why it matters beyond the novelty: LSD and psilocybin don't touch the cerebellum this way, so mescaline is running at least partly on its own wiring despite producing the same broad hallmarks of a trip. And the selective breakdown in sensory gating rhymes with what shows up in schizophrenia and PTSD, which is why the authors think mescaline could become a tool for modeling those conditions rather than only a curiosity.

The honest caveats: these are rats, not people. It is one study. Awake-animal fMRI is a young technique with its own quirks. This is a first photograph, not a finished map. But it is the first real photograph we have of the oldest psychedelic doing its work.

Market Watch

The capital isn't waiting for the maps. On July 16, Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion, its first serious move into psychedelic medicine, built around a DMT-like compound for depression. It is the first time a top-tier pharmaceutical company has put blue-chip money on the table for this space, and the rest of the sector repriced within days as investors reread every smaller company against Lilly's bet.

Worth connecting the threads: DMT was the single strongest responder in that five-drug brain study now making the rounds. The molecules that share mescaline's ancient lineage — the classic tryptamines and phenethylamines people have used for millennia — are, this month, blue-chip acquisition targets. The cactus did it for free. The pipeline costs billions.

The Last Word

There is a joke somewhere about spending $3.8 billion to catch up to something a desert plant has been doing since the Stone Age, and I'll let you write it. What the Northeastern scan actually offers is smaller and stranger than a punchline: a picture, at last, of what happens inside a brain on the first drug we ever named a ceremony around.

The people who used peyote for five thousand years didn't have an MRI. They had ritual, attention, elders, and each other, and they came to their own conclusions about what the medicine was for. The new science isn't correcting them. It's arriving late to a conversation that started a very long time ago, pulling up a chair, and taking notes.

— The Alkaloid

Sources

• Northeastern Global News, "One of the oldest psychedelics meets modern brain imaging" (July 20, 2026)
• Cavallaro N., Ferris C.F. et al., "Mescaline Alters Cerebellar Function, Global Connectivity, and Frequency-Selective Acoustic Gating: A BOLD fMRI Study in Awake Rats," Neuroscience Bulletin (May 21, 2026)
• The Marijuana Herald / Cannabis Science & Technology, on the Israeli terpene–cannabinoid receptor study (July 2026)
• ScienceDaily, "Scientists found a cannabis compound that relieves pain without the high" (June 2026)
• Girn M., Bzdok D. et al., "An international mega-analysis of psychedelic drug effects on brain circuit function," Nature Medicine (2026)
• CNBC / Axios / BNN Bloomberg, on Eli Lilly's acquisition of AtaiBeckley (July 16, 2026)

The Alkaloid publishes every Tuesday. Forward this to someone who needs the dose. Subscribe for full access: TheAlkaloid.com